Deep Dive with Lindsay Hill, DNP, PMHNP - Psych NP Mentor - PMHNP Mentor

Deep Dive with Lindsay Hill, DNP, PMHNP - Psych NP Mentor - PMHNP Mentor

By Lindsay HillHealth & FitnessMental HealthEducationCourses
Download on the App Store

Deep Dive with Lindsay Hill, DNP, PMHNP - Psych NP Mentor - PMHNP Mentor episodes

  • S2E59: PMHNP Business Entity: PLLC vs. S-Corp Tax Playbook for 2026

    Hey! I'd love to hear your thoughts, send me a voice note.

    In this deep-dive episode, we unpack PMHNP Business Entity: PLLC vs. S-Corp Tax Playbook for 2026.
    Audio Overview Listen to an in-depth podcast of this post Two hosts break down the full article — no reading required. Your browser does not support audio playback. TL;DR A PMHNP netting $220,000 in a sole-prop PLLC pays ~$9,500 more per year in self-employment tax than one who filed the S-Corp election. The PLLC is a liability shield; S-Corp is a separate federal tax election on IRS Form 2553. The election becomes worth the payroll and compliance overhead when net practice profit crosses roughly $60,000–$80,000. Pay yourself a documented “reasonable salary” — typically 40–60% of profit in early years — and take the rest as distributions to avoid self-employment tax on that portion. File Form 2553 before March 15 of the election year. In This Article → LLC, PLLC, and S-Corp — Three Differe
    Read the full post: https://psychnpfellowship.com/pmhnp-pllc-vs-s-corp-business-entity-tax-2026/
    22 min
  • S2E1: Bysanti (Milsaperidone) FDA Approval: What PMHNPs Need to Know

    Hey! I'd love to hear your thoughts, send me a voice note.

    In this deep-dive episode, we unpack Bysanti (Milsaperidone) FDA Approval: What PMHNPs Need to Know.
    Bysanti (milsaperidone) is a newly FDA-approved atypical antipsychotic with a unique dual mechanism — partial D2 agonism combined with 5-HT2A inverse agonism — designed to reduce metabolic side effects and EPS risk compared to older atypicals. It’s approved for schizophrenia and bipolar I maintenance in adults. For PMHNPs, this means a new tool with a potentially better tolerability profile, but it requires understanding the monitoring protocol and where it fits in your prescribing algorithm before reaching for it.
    Read the full post: https://psychnpfellowship.com/bysanti-milsaperidone-fda-approval-pmhnp-guide/
    22 min
  • S1E24: Your Patients Are Already Using AI for Therapy — What PMHNPs Need to Ask

    Hey! I'd love to hear your thoughts, send me a voice note.

    In this episode of Deep Dive with Lindsay Hill, we tackle a clinical reality that most psychiatric providers aren't yet addressing: millions of patients are using AI chatbots for emotional support and mental health guidance, and they're not telling you about it. Drawing from a recent JAMA Psychiatry paper by Shaddy Saba at NYU, Lindsay breaks down why asking about AI use should become as routine as screening for sleep, substance use, or medication adherence. This isn't about technology trends—it's about patient safety, treatment planning, and understanding the full clinical picture. You'll learn: (1) why patients turn to AI chatbots and why they don't disclose it, (2) how AI-generated advice can interfere with your treatment plan or miss escalating symptoms, (3) the safety concerns including deceptive empathy, missed suicidal ideation, and reinforced delusions in vulnerable populations, (4) how to incorporate nonjudgmental AI screening questions into your patient interviews starting in clinical rotations, and (5) what the current regulatory vacuum means for your practice and advocacy role as a future PMHNP. Lindsay also explores the distinction between supervised AI tools that support clinical care versus unsupervised chatbot use as a therapy substitute, and why understanding this landscape will make you a more comprehensive, thoughtful provider in a field facing a critical workforce shortage. For further reading: https://pmhnpreview.org/your-patients-are-already-using-ai-for-therapy-heres-what-every-pmhnp-student-needs-to-know/
    21 min
  • S1E23: Pramipexole for Treatment-Resistant Depression — Dopamine Augmentation, the PAX-D Trial, and What Most Clinicians Get Wrong

    Hey! I'd love to hear your thoughts, send me a voice note.

    In this episode of Deep Dive with Lindsay Hill, we explore pramipexole (Mirapex) as an evidence-based augmentation strategy for treatment-resistant unipolar depression. Lindsay breaks down the PAX-D trial published in The Lancet Psychiatry, which demonstrated significant symptom reduction at 12 weeks that persisted through 48 weeks when pramipexole was added to existing antidepressants at a target dose of 2.5 mg/day. You'll learn why dopamine matters when serotonergic strategies have failed, particularly in patients with anhedonia, low motivation, and psychomotor slowing. Lindsay walks through the precise titration protocol that separates success from early discontinuation, explains why most clinicians stop too early at subtherapeutic doses, and details the critical safety monitoring required for impulse control disorders including compulsive gambling, hypersexuality, and binge eating. You'll also hear where pramipexole fits in the treatment algorithm after two or more failed antidepressant trials, how to minimize nausea during titration, and why this dopamine D3 agonist works through postsynaptic receptor activation in the mesolimbic reward pathway. This episode gives PMHNPs and advanced-practice psych clinicians a practical, evidence-backed tool for patients who've been stuck for months or years. For further reading: https://psychnpfellowship.com/pramipexole-treatment-resistant-depression-pmhnp-guide/
    24 min
  • S1E22: The 2025 APA PTSD Guideline — Three Therapies, Zero Benzos, and What Changed

    Hey! I'd love to hear your thoughts, send me a voice note.

    In this episode of Deep Dive with Lindsay Hill, we break down the American Psychological Association's first new PTSD guideline in eight years — and why it matters for every PMHNP student sitting for boards or walking into their first clinical rotation. Released in February 2025, this updated Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults expands the evidence base from one systematic review to fifteen, addresses complex trauma presentations head-on, and gives us a clearer roadmap for first-line treatment than we've had in nearly a decade. You'll learn: (1) the three psychotherapies with the strongest evidence — Cognitive Processing Therapy, Prolonged Exposure, and Trauma-Focused CBT — and why these are the names you need to say out loud when a patient asks what works; (2) the pharmacotherapy hierarchy every prescriber must know cold: SSRIs and SNRIs first, prazosin for nightmares, and the firm recommendation against benzodiazepines for PTSD treatment; (3) why emerging treatments like MDMA-assisted therapy and ketamine are not yet guideline-endorsed, and how to talk to patients who ask about them; (4) the HISTORY framework for complex PTSD — a clinical tool that prioritizes stabilization, readiness, and therapeutic alliance before diving into trauma-focused work; and (5) how to translate this guideline into board-ready answers and patient-centered care that reflects the current standard of practice. This is the version that will shape your exam questions, your referral pathways, and your prescribing decisions for years to come. For further reading: https://pmhnpreview.org/the-apa-just-released-its-first-new-ptsd-guideline-in-8-years-heres-what-every-pmhnp-student-needs-to-know/
    21 min
  • Courtrooms, Classrooms, and Clinics: The Modern Autistic Youth

    Hey! I'd love to hear your thoughts, send me a voice note.

    Welcome to Courtrooms, Classrooms, and Clinics, a deep dive into the complex, multidisciplinary realities of supporting autistic adolescents today. In this episode, we explore how the challenges autistic youth face extend far beyond traditional therapy, requiring a unified approach across every aspect of their lives.

    • In the Clinic: We tackle urgent and often misunderstood clinical truths. Did you know that autistic youth are five times as likely to attempt suicide compared to their neurotypical peers? We discuss why these unique warning signs are so easily missed, how providers can adapt standard screening tools, and the hidden drivers behind substance use as teens try to manage severe anxiety or simply fit in socially.
    • In the Courtroom: When parents of autistic children separate, disagreements over therapies, education, and diagnoses can escalate into intense custody battles. We explore the legal landscape with expert insights on how clinicians can help judges understand a child's unique developmental needs, without overstepping ethical boundaries or getting caught in the crossfire.
    • In the Classroom (and Beyond): We address the dreaded "service cliff" that awaits autistic teens as they age out of school-based support and transition to adulthood. We share actionable insights on why teaching executive functioning skills as early as middle school is the ultimate key to unlocking better adult outcomes—from pursuing higher education and employment to gaining independence behind the wheel.

    Whether you are a psychiatrist, therapist, educator, or caregiver, join us as we rethink how to best support, protect, and empower the modern autistic youth across all environments.

    21 min
  • Brexpiprazole for Dementia & PTSD, Perinatal Mental Health, and New Research

    Hey! I'd love to hear your thoughts, send me a voice note.

    This episode reviews brexpiprazole's expanding FDA indications, including its approval for agitation in Alzheimer's dementia and mixed results in PTSD augmentation. Dr. Amritha Bhat discusses perinatal mental health, covering antidepressant safety in pregnancy, postpartum psychosis as a bipolar spectrum disorder, and zuranolone for postpartum depression. Also featured: new research on service dogs for PTSD, placebo responses across psychiatric disorders, vitamin D's dose-dependent antidepressant effects, and metformin guidelines for preventing antipsychotic weight gain.
    20 min
  • Navigating Reproductive Psychiatry: Bipolar, Depression, and Postpartum Psychosis

    Hey! I'd love to hear your thoughts, send me a voice note.

    In this episode, we dive into the critical field of reproductive psychiatry to equip psychiatric nurse practitioners with the latest evidence-based strategies for managing pregnant and postpartum patients.... Listeners will learn how to differentiate psychiatric emergencies like postpartum psychosis from postpartum obsessive-compulsive disorder, and navigate complex medication decisions involving lithium, valproic acid, and novel treatments for postpartum depression like zuranolone.... We explore crucial clinical insights, including the necessity of adjusting lamotrigine and lithium doses during pregnancy and the importance of maintaining antidepressant regimens to prevent high relapse rates.... By understanding the nuanced risks of medication exposure versus untreated maternal illness, you will be empowered to conduct confident risk-benefit discussions and provide life-saving, collaborative care to this vulnerable population....
    21 min
  • Navigating Scope of Practice, Antipsychotic Switches, and Severe OCD Cases

    Hey! I'd love to hear your thoughts, send me a voice note.

    Join this insightful peer consultation session where psychiatric nurse practitioners navigate the complexities of clinical decision-making and private practice dynamics. The group explores the nuances of scope of practice, specifically debating when to manage medical comorbidities like migraines or withdrawal symptoms and the utility of "two-for-one" medications like topiramate. Listeners will gain practical strategies for switching antipsychotics, including specific tips on cross-tapering versus direct switching based on receptor occupancy. The episode also features a deep dive into a severe, treatment-resistant OCD case, examining augmentation strategies, TMS, and the critical role of Exposure and Response Prevention (ERP) therapy. These real-world discussions provide valuable support and clinical pearls for PMHMPs seeking to enhance their psychopharmacology skills and navigate complex patient scenarios.
    18 min
  • When SSRIs Fail in OCD and Collaborative Suicide Assessment

    Hey! I'd love to hear your thoughts, send me a voice note.

    This episode dives into evidence-based strategies for treating Obsessive-Compulsive Disorder when first-line SSRIs fail, exploring augmentation options like ondansetron, memantine, and deep TMS.... We also sit down with Dr. David Jobes to discuss the Collaborative Assessment and Management of Suicidality (CAMS), a transformative framework that empowers patients by focusing on their specific drivers of suffering rather than just risk prediction45. Additionally, the discussion covers the rising popularity of transcranial direct current stimulation (tDCS), offering a clinical verdict on its safety and efficacy for depression compared to established treatments67. Finally, we review a recent meta-analysis regarding antipsychotic dosing, highlighting crucial differences in optimal therapeutic levels for acute mania versus schizophrenia89. Join us to expand your psychopharmacology toolkit and gain practical, life-saving insights for your most complex cases.
    15 min

About Deep Dive with Lindsay Hill, DNP, PMHNP - Psych NP Mentor - PMHNP Mentor

From the publisher's feed

Welcome to my podcast. I am Lindsay Hill, DNP, PMHNP BC, and this show is my space to slow down and really unpack what psychiatric care looks like in real life.

Each episode is built from the…